TY - JOUR
T1 - Value-of-Information Analysis within a Stakeholder-Driven Research Prioritization Process in a US Setting
T2 - An Application in Cancer Genomics
AU - Carlson, Josh J.
AU - Thariani, Rahber
AU - Roth, Josh
AU - Gralow, Julie
AU - Henry, N. Lynn
AU - Esmail, Laura
AU - Deverka, Pat
AU - Ramsey, Scott D.
AU - Baker, Laurence
AU - Veenstra, David L.
N1 - Funding Information:
Previously presented at ISPOR 16th Annual International Meeting; 21–25 May 2011, Baltimore, Maryland. This work was supported by the Centers for Disease Control and Prevention (grant number 1U18GD000005) and by the National Cancer Institute at the National Institutes of Health (grant number: CA148570).
PY - 2013/5
Y1 - 2013/5
N2 - Objective. The objective of this study was to evaluate the feasibility and outcomes of incorporating value-of-information (VOI) analysis into a stakeholder-driven research prioritization process in a US-based setting. Methods. Within a program to prioritize comparative effectiveness research areas in cancer genomics, over a period of 7 months, we developed decision-analytic models and calculated upper-bound VOI estimates for 3 previously selected genomic tests. Thirteen stakeholders representing patient advocates, payers, test developers, regulators, policy makers, and community-based oncologists ranked the tests before and after receiving VOI results. The stakeholders were surveyed about the usefulness and impact of the VOI findings. Results. The estimated upper-bound VOI ranged from $33 million to $2.8 billion for the 3 research areas. Seven stakeholders indicated the results modified their rankings, 9 stated VOI data were useful, and all indicated they would support its use in future prioritization processes. Some stakeholders indicated expected value of sampled information might be the preferred choice when evaluating specific study designs. Limitations. Our study was limited by the size and the potential for selection bias in the composition of the external stakeholder group, lack of a randomized design to assess effect of VOI data on rankings, and the use of expected value of perfect information v. expected value of sample information methods. Conclusions. Value of information analyses may have a meaningful role in research topic prioritization for comparative effectiveness research in the United States, particularly when large differences in VOI across topic areas are identified. Additional research is needed to facilitate the use of more complex value of information analyses in this setting.
AB - Objective. The objective of this study was to evaluate the feasibility and outcomes of incorporating value-of-information (VOI) analysis into a stakeholder-driven research prioritization process in a US-based setting. Methods. Within a program to prioritize comparative effectiveness research areas in cancer genomics, over a period of 7 months, we developed decision-analytic models and calculated upper-bound VOI estimates for 3 previously selected genomic tests. Thirteen stakeholders representing patient advocates, payers, test developers, regulators, policy makers, and community-based oncologists ranked the tests before and after receiving VOI results. The stakeholders were surveyed about the usefulness and impact of the VOI findings. Results. The estimated upper-bound VOI ranged from $33 million to $2.8 billion for the 3 research areas. Seven stakeholders indicated the results modified their rankings, 9 stated VOI data were useful, and all indicated they would support its use in future prioritization processes. Some stakeholders indicated expected value of sampled information might be the preferred choice when evaluating specific study designs. Limitations. Our study was limited by the size and the potential for selection bias in the composition of the external stakeholder group, lack of a randomized design to assess effect of VOI data on rankings, and the use of expected value of perfect information v. expected value of sample information methods. Conclusions. Value of information analyses may have a meaningful role in research topic prioritization for comparative effectiveness research in the United States, particularly when large differences in VOI across topic areas are identified. Additional research is needed to facilitate the use of more complex value of information analyses in this setting.
KW - decision analysis
KW - economic analysis
KW - value of information
UR - http://www.scopus.com/inward/record.url?scp=84877063014&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877063014&partnerID=8YFLogxK
U2 - 10.1177/0272989X13484388
DO - 10.1177/0272989X13484388
M3 - Article
C2 - 23635833
AN - SCOPUS:84877063014
SN - 0272-989X
VL - 33
SP - 463
EP - 471
JO - Medical Decision Making
JF - Medical Decision Making
IS - 4
ER -